A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C CT Wai, JK Greenson, RJ Fontana, JD Kalbfleisch, JA Marrero, ... Hepatology 38 (2), 518-526, 2003 | 4996 | 2003 |
Chronic hepatitis B ASF Lok, BJ McMahon Hepatology 45 (2), 507-539, 2007 | 4508 | 2007 |
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance NA Terrault, ASF Lok, BJ McMahon, KM Chang, JP Hwang, MM Jonas, ... Hepatology 67 (4), 1560-1599, 2018 | 4133 | 2018 |
Chronic hepatitis B: update 2009 ASF Lok, BJ McMahon Hepatology 50 (3), 661-662, 2009 | 3954 | 2009 |
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B TT Chang, RG Gish, R De Man, A Gadano, J Sollano, YC Chao, AS Lok, ... New England Journal of Medicine 354 (10), 1001-1010, 2006 | 2079 | 2006 |
Hepatitis B virus infection C Trépo, HLY Chan, A Lok The Lancet 384 (9959), 2053-2063, 2014 | 1957 | 2014 |
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B CL Lai, D Shouval, AS Lok, TT Chang, H Cheinquer, Z Goodman, ... New England Journal of Medicine 354 (10), 1011-1020, 2006 | 1695 | 2006 |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1585 | 2014 |
Chronic hepatitis B ASF Lok, BJ McMahon Hepatology 34 (6), 1225-1241, 2001 | 1457 | 2001 |
Management of hepatitis B: 2000—summary of a workshop AS Lok, EJ Heathcote, JH Hoofnagle Gastroenterology 120 (7), 1828-1853, 2001 | 1391 | 2001 |
Long-term safety of lamivudine treatment in patients with chronic hepatitis B ASF Lok, CL Lai, N Leung, GB Yao, ZY Cui, ER Schiff, JL Dienstag, ... Gastroenterology 125 (6), 1714-1722, 2003 | 1215 | 2003 |
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study ASF Lok, RHS Liang, EKW Chiu, KL Wong, TK Chan, D Todd Gastroenterology 100 (1), 182-188, 1991 | 1098 | 1991 |
Management of hepatitis B: summary of a clinical research workshop JH Hoofnagle, E Doo, TJ Liang, R Fleischer, ASF Lok Hepatology 45 (4), 1056-1075, 2007 | 1089 | 2007 |
Chronic hepatitis B: update of recommendations ASF Lok, BJ McMahon Hepatology 39 (3), 857-861, 2004 | 927 | 2004 |
α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma JA Marrero, Z Feng, Y Wang, MH Nguyen, AS Befeler, LR Roberts, ... Gastroenterology 137 (1), 110-118, 2009 | 890 | 2009 |
Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005 HJ Yim, ASF Lok Hepatology 43 (S1), S173-S181, 2006 | 828 | 2006 |
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States JA Marrero, RJ Fontana, GL Su, HS Conjeevaram, DM Emick, AS Lok Hepatology 36 (6), 1349-1354, 2002 | 828 | 2002 |
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort JA Marrero, RJ Fontana, A Barrat, F Askari, HS Conjeevaram, GL Su, ... Hepatology 41 (4), 707-715, 2005 | 810 | 2005 |
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease AS Lok, LB Seeff, TR Morgan, AM Di Bisceglie, RK Sterling, TM Curto, ... Gastroenterology 136 (1), 138-148, 2009 | 809 | 2009 |
Preliminary study of two antiviral agents for hepatitis C genotype 1 AS Lok, DF Gardiner, E Lawitz, C Martorell, GT Everson, R Ghalib, ... New England Journal of Medicine 366 (3), 216-224, 2012 | 750 | 2012 |